Kosmas Daskalakis

Dr. Kosmas Daskalakis

Department of Surgery, Faculty of Medicine and Health, Örebro University, 701 85 Örebro, Sweden.
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
KDKosmas Daskalakis
Kosmas Daskalakis
AKAndreas Karakatsanis
Andreas Karakatsanis
OHOla Hessman
Ola Hessman
HSHeather C. Stuart
Heather C. Stuart
SWStaffan Welin
Staffan Welin
Peter StålbergPeter Stålberg
Peter Stålberg
Small intestinal neuroendocrine tumors (SI-NETs) have an indolent clinical course and are often diagnosed at a late stage.1 Sixty percent of patients with SI-NETs present with distant metastases, most commonly in the liver; thus, a high proportion of patients are diagnosed with stage IV tumors.1,2

1 January 2017 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
KDKosmas Daskalakis
Kosmas Daskalakis
AKA. Karakatsanis
A. Karakatsanis
Peter StålbergPeter Stålberg
Peter Stålberg
ONO. Norlén
O. Norlén
PHP. Hellman
P. Hellman

3 June 2019 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
ECEleftherios Chatzellis
Eleftherios Chatzellis
AAAnna Angelousi
Anna Angelousi
KDKosmas Daskalakis
Kosmas Daskalakis
MTMarina Tsoli
Marina Tsoli
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
Background: Capecitabine and temozolomide combination (CAPTEM) is associated with high response rates in patients with advanced neuroendocrine neoplasms (NENs). We evaluated the real-world activity and safety of CAPTEM from 3 NEN centers. Methods: Clinicopathological characteristics and outcomes of patients treated with CAPTEM for bulky or progressive disease (PD) were retrospectively analyzed. ­Results: Seventy-nine patients with gastroenteropancreatic (grades 1–2 [n = 38], grade 3 [n = 24]) and lung/thymic (n = 17) NENs were included. Median treatment duration was 12.1 months (range 0.6–55.6). Overall, partial responses (PRs) occurred in 23 (29.1%), stable (SD) in 24 (30.4%), and PD in 28 (35.4%) patients. Median progression-free survival (PFS) and overall survival (OS) were 10.1 (6–14.2) and 102.9 months (43.3–162.5), respectively. On univariate analysis, NENs naive to chemotherapy and low Ki67 were associated with favorable responses (partial response [PR] + SD; p = 0.011 and 0.045), PFS (p < 0.0001 and 0.002) and OS (p = 0.005 and 0.001). Primary site (pancreas and lung/thymus) was also a significant prognostic factor for PFS (p < 0.0001) and OS (p < 0.0001). On multivariate analysis, gastrointestinal and unknown primary NENs (hazard ratio [HR] 0.3, 95% CI 0.1–0.8, p = 0.009 and p = 0.018) and prior surgery (HR 2.4, 95% CI 11–4.9, p = 0.021) were independent prognostic factors for PFS. Ki-67 was a poor predictor for favorable response in receiver operating characteristic analysis (area under the curve 0.678). Safety analysis of CAPTEM indicated rare events of serious (grades 3–4) toxicities (n = 4) and low discontinuation rates (n = 8) even in patients with prolonged administration (>12 months). Conclusions: CAPTEM treatment can be an effective and safe treatment even after prolonged administration for patients with NENs of various sites and Ki67 labeling index, associated with significant favorable responses and PFS.

10 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EAEmmanouil Alevroudis
Emmanouil Alevroudis
MSMaria-Eleni Spei
Maria-Eleni Spei
SCsofia chatziioannou
sofia chatziioannou
MTMarina Tsoli
Marina Tsoli
GWGöran Wallin
Göran Wallin
KDKosmas Daskalakis
Kosmas Daskalakis
The role of 18F-FDG PET in patients with variable grades of neuroendocrine tumors (NETs) prior to peptide receptor radionuclide therapy (PRRT) has not been adequately elucidated. We aimed to evaluate the impact of 18F-FDG PET status on disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in neuroendocrine tumor (NET) patients receiving PRRT. We searched the MEDLINE, Embase, Cochrane Library, and Web of Science databases up to July 2020 and used the Newcastle-Ottawa scale (NOS) criteria to assess quality/risk of bias. A total of 5091 articles were screened. In 12 studies, 1492 unique patients with NETs of different origins were included. The DCR for patients with negative 18F-FDG PET status prior to PRRT initiation was 91.9%, compared to 74.2% in patients with positive 18F-FDG PET status (random effects odds ratio (OR): 4.85; 95% CI: 2.27–10.36). Adjusted analysis of pooled hazard ratios (HRs) confirmed longer PFS and OS in NET patients receiving PRRT with negative 18F-FDG PET (random effects HR:2.45; 95%CIs: 1.48–4.04 and HR:2.25; 95% CIs:1.55–3.28, respectively). In conclusion, 18F-FDG PET imaging prior to PRRT administration appears to be a useful tool in NET patients to predict tumor response and survival outcomes and a negative FDG uptake of the tumor is associated with prolonged PFS and OS.

Verified
Journal Article
Open access
PDF file
AKAnna Koumarianou
Anna Koumarianou
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
GWGöran Wallin
Göran Wallin
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
KDKosmas Daskalakis
Kosmas Daskalakis
Mesenteric fibrosis (MF) constitutes an underrecognized sequela in patients with small intestinal neuroendocrine neoplasms (SI-NENs), often complicating the disease clinical course. The aim of the present systematic review, carried out by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology, is to provide an update in evolving aspects of MF pathogenesis and its clinical management in SI-NENs. Complex and dynamic interactions are present in the microenvironment of tumor deposits in the mesentery. Serotonin, as well as the signaling pathways of certain growth factors play a pivotal, yet not fully elucidated role in the pathogenesis of MF. Clinically, MF often results in significant morbidity by causing either acute complications, such as intestinal obstruction and/or acute ischemia or more chronic conditions involving abdominal pain, venous stasis, malabsorption and malnutrition. Surgical resection in patients with locoregional disease only or symptomatic distant stage disease, as well as palliative minimally invasive interventions in advanced inoperable cases seem clinically meaningful, whereas currently available systemic and/or targeted treatments do not unequivocally affect the development of MF in SI-NENs. Increased awareness and improved understanding of the molecular pathogenesis of MF in SI-NENs may provide better diagnostic and predictive tools for its timely recognition and intervention and also facilitates the development of agents targeting MF.

6 September 2019 in Endocrine
Verified
Journal Article
Open access
PDF file
KDKosmas Daskalakis
Kosmas Daskalakis
KAKrystallenia Alexandraki
Krystallenia Alexandraki
EKEvanthia Kassi
Evanthia Kassi
MTMarina Tsoli
Marina Tsoli
AAAnna Angelousi
Anna Angelousi
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
Background There are no clear histopathological parameters determining the risk of lymph node (LN) metastases and appropriateness of completion prophylactic right hemicolectomy (RHC) in patients with appendiceal neuroendocrine neoplasms (ANENs). Materials and methods The PubMed, Cochrane Library, Embase, Web of Science and SCOPUS databases were searched up to November 2018. Quality/risk of bias was assessed using the Newcastle–Ottawa Scale (NOS). Results A total of 526 articles were screened. In 11 adult and 3 paediatric studies, 602 and 77 unique patients, respectively, with ANEN and undergoing RHC, were included. The rate of LN metastases for a cutoff size >10 mm was 48.6% (vs 12.1% for lesions <10 mm) among adult patients, with an odds ratio (OR) of 4.8 (95% CI, 1.5–15.8). For 20 mm size cutoff, these figures were 61% (vs 28.2% for lesions 20 mm as well as >10 mm and/or vascular-, lymph vessel- and perineural invasions are associated with increased risk for LN metastases in adult patients with ANEN. The prognostic value of LN positivity remains to be determined in further studies with long-term follow-up.